151 related articles for article (PubMed ID: 34325089)
21. Imaging Bradykinin B1 Receptor with 68Ga-Labeled [des-Arg10]Kallidin Derivatives: Effect of the Linker on Biodistribution and Tumor Uptake.
Amouroux G; Pan J; Jenni S; Zhang C; Zhang Z; Hundal-Jabal N; Colpo N; Liu Z; Bénard F; Lin KS
Mol Pharm; 2015 Aug; 12(8):2879-88. PubMed ID: 26101793
[TBL] [Abstract][Full Text] [Related]
22. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
24. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides.
Vegt E; Eek A; Oyen WJ; de Jong M; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):226-34. PubMed ID: 19722105
[TBL] [Abstract][Full Text] [Related]
25. Future direction of renal positron emission tomography.
Szabo Z; Xia J; Mathews WB; Brown PR
Semin Nucl Med; 2006 Jan; 36(1):36-50. PubMed ID: 16356795
[TBL] [Abstract][Full Text] [Related]
26. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
27. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
28. Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics.
Ogawa K
Chem Pharm Bull (Tokyo); 2019; 67(9):897-903. PubMed ID: 31474726
[TBL] [Abstract][Full Text] [Related]
29. Analysis of renal handling of radiopharmaceuticals.
Trejtnar F; Laznicek M
Q J Nucl Med; 2002 Sep; 46(3):181-94. PubMed ID: 12134135
[TBL] [Abstract][Full Text] [Related]
30. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations.
Behr TM; Goldenberg DM; Becker W
Eur J Nucl Med; 1998 Feb; 25(2):201-12. PubMed ID: 9473271
[TBL] [Abstract][Full Text] [Related]
31. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract][Full Text] [Related]
32. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
33. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
34. Enzymological Characterization of
Brandt F; Ullrich M; Wodtke J; Kopka K; Bachmann M; Löser R; Pietzsch J; Pietzsch HJ; Wodtke R
J Med Chem; 2023 Jan; 66(1):516-537. PubMed ID: 36595224
[TBL] [Abstract][Full Text] [Related]
35. Diabody Pretargeting with Click Chemistry In Vivo.
van Duijnhoven SM; Rossin R; van den Bosch SM; Wheatcroft MP; Hudson PJ; Robillard MS
J Nucl Med; 2015 Sep; 56(9):1422-8. PubMed ID: 26159589
[TBL] [Abstract][Full Text] [Related]
36. Vaginal distribution and retention of a multiparticulate drug delivery system, assessed by gamma scintigraphy and magnetic resonance imaging.
Mehta S; Verstraelen H; Peremans K; Villeirs G; Vermeire S; De Vos F; Mehuys E; Remon JP; Vervaet C
Int J Pharm; 2012 Apr; 426(1-2):44-53. PubMed ID: 22265911
[TBL] [Abstract][Full Text] [Related]
37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
38. Radiation dose in nuclear medicine: the hybrid imaging.
Salvatori M; Rizzo A; Rovera G; Indovina L; Schillaci O
Radiol Med; 2019 Aug; 124(8):768-776. PubMed ID: 30771217
[TBL] [Abstract][Full Text] [Related]
39. [Contrast-induced acute renal failure].
Giannattasio M
G Ital Nefrol; 2005; 22(3):217-25. PubMed ID: 16001365
[TBL] [Abstract][Full Text] [Related]
40. Non-Invasive Imaging Methodologies for Assessment of Radiation Damage to Bone Marrow and Kidneys from Peptide Receptor Radionuclide Therapy.
Ahlstedt J; Johansson E; Sydoff M; Karlsson H; Thordarson E; Gram M; Eriksson O
Neuroendocrinology; 2020; 110(1-2):130-138. PubMed ID: 30999299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
